Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Study 2: deep breathing, Study 2: 4-7-8 breathing, Study 2: slow breathing with device.
- Who it may be relevant to
- Registry conditions: Genetic Predisposition to Disease, Breathing, Mouth. Basic parameters: 18 years — 59 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Thailand
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Expression of Genes Relating Hypertension in Thailand and the Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure in Individuals With Hypertension
Overview
This study consists of two sub-studies. Study 1 investigates gene expression related to the development of hypertension in Thailand, and Study 2 examines the effectiveness of the 4-7-8 breathing technique in reducing blood pressure in individuals with hypertension.
Detailed description
In Study 1, the sample group includes 200 individuals aged 18-59 years, originating from various regions of Thailand but currently residing in the eastern region. Participants may have normal blood pressure, high blood pressure, or have been diagnosed with hypertension. Blood samples from the participants will be analyzed for the following variables: 1) expression of five genes-adrenomedullin (ADM), angiopoietin-like 4 (ANGPTL4), proto-oncogene c-Fos (FOS), prostaglandin-endoperoxide synthase 2 (PTGS2), and ubiquitin specific peptidase 8 (USP8), and 2) markers of inflammation-tumor necrosis factor-alpha and interferon-gamma levels in the blood.
In Study 2, the sample group includes 75 volunteers from Study 1 who are interested in participating. These volunteers will be randomly assigned into three groups of 25 people each. The first group is a control group whose participants will not receive any breathing training. The second group will practice the 4-7-8 breathing technique, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds-this constitutes one cycle. They will repeat this for 6 cycles per set, three sets per day, with normal breathing between sets. The third group will practice deep diaphragmatic breathing at a rate of 6-10 breaths per minute for 15 minutes, twice a day. Participants in both the second and third groups are required to follow their assigned breathing programs daily for three consecutive months. At the end of the three months, all participants will be assessed on the same variables measured before the intervention: 1) systolic and diastolic blood pressure levels, 2) blood pressure variability, and 3) inflammation markers, specifically tumor necrosis factor-alpha and interferon-gamma levels in the blood.
Interventions
- Other Study 2: deep breathing
Participants in the deep breathing group will be randomized to receive a diaphragmatic deep breathing program. They will be instructed to practice deep breathing at a rate of 6-10 breaths per minute for 15 minutes, twice daily, every day for a duration of 3 months. - Other Study 2: 4-7-8 breathing
Participants in the 4-7-8 breathing group will be randomized to receive a 4-7-8 breathing program. They will follow the 4-7-8 breathing training program, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds, counted as one cycle. This pattern is to be repeated for 6 cycles to complete one set. They will perform 12 sets per day-6 sets in the morning and 6 sets in the evening-with normal breathing between each set. This routine will be carried out dai - Other Study 2: slow breathing with device
Participants in the slow breathing with device group will be randomized to receive a slow breathing with device. They will undergo deep breathing training using a resistance-based breathing device called BreathMax, set at 25% of their maximal inspiratory pressure. The breathing rate will be 6 breaths per minute, continuously for 15 minutes, twice a day. This routine will be performed daily for a duration of 3 months.
Primary outcome measures
- Study 1: expression of adrenomedullin (ADM) [Time frame: Day 1]
- Study 1: expression of angiopoietin-like 4 (ANGPTL4) [Time frame: Day 1]
- Study 1: expression of proto-oncogene c-Fos (FOS) [Time frame: Day 1]
- Study 1: expression of prostaglandin-endoperoxide synthase 2 (PTGS2) [Time frame: Day 1]
- Study 1: expression of ubiquitin specific peptidase 8 (USP8) [Time frame: Day 1]
- Study 1: tumor necrosis factor-alpha [Time frame: Day 1]
- Study 1: interferon-gamma [Time frame: Day 1]
- Study 2: systolic blood pressure [Time frame: Day 1 and Day 85]
- Study 2: diastolic blood pressure [Time frame: Day 1 and Day 85]
- Study 2: systolic blood pressure coefficient of variation [Time frame: Day 1 and Day 85]
Eligibility criteria
Study 1:
- Group of individuals with hypertension
Inclusion criteria
- Male or female
- Aged between 18-59 years
- Of Thai ethnicity
- Diagnosed with hypertension, defined as having an SBP of 140 mmHg or higher, or a DBP of 90 mmHg or higher, or having previously been diagnosed with hypertension and currently taking antihypertensive medication
- Originally from various regions of Thailand and currently residing in the eastern region
Exclusion criteria
- Has heart disease, such as valvular stenosis or regurgitation, coronary artery disease, or heart failure
- Has obesity, defined as having a body mass index (BMI) of 30 kg/m² or higher
- Has a fever or is currently experiencing an infectious disease, such as COVID-19, the flu, or other infections
- Group of individuals with normal blood pressure
Inclusion criteria
- Male or female
- Aged between 18-59 years
- Of Thai ethnicity
- Does not have hypertension, defined as having an SBP below 130 mmHg and a DBP below 85 mmHg, with no prior diagnosis of hypertension and no history of taking antihypertensive medication
- Originally from various regions of Thailand and currently residing in the eastern region
Exclusion criteria
- Has heart disease, such as valvular stenosis or regurgitation, coronary artery disease, or heart failure
- Has obesity, defined as having a body mass index (BMI) of 30 kg/m² or higher
- Has a fever or is currently experiencing an infectious disease, such as COVID-19, the flu, or other infections
Study 2:
Inclusion criteria
- Male or female, aged 35-59 years
- Diagnosed with hypertension, with blood pressure levels above the normal range, defined as SBP of 130 mmHg or higher, or DBP of 85 mmHg or higher, and currently taking medication
- Originally from various regions of Thailand and currently residing in the eastern region
- Able to communicate effectively
Exclusion criteria
- Has respiratory diseases, cardiovascular diseases, cerebrovascular disease, kidney disease, cancer, or immune-related conditions such as allergies, autoimmune diseases (e.g., SLE), immunodeficiency, or rheumatoid arthritis
- Is obese, defined as having a body mass index (BMI) of 30 kg/m² or higher
- Has a fever or is currently infected, such as with COVID-19, the flu, or other infectious diseases
- Is currently pregnant, breastfeeding, or has a history of pregnancy within the 6 months prior to participating in the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Basic science
Study locations
Thailand · 1 center
- Faculty of Allied Health Sciences, Burapha University — MueangChonburi
Identifiers
NCT: NCT07018128 · IRB1-046/2568